 |
 |
 |
 |
 |
 |
 |
 |
Esma S. Yolcu, Ph.D.
Intro | Research Interests |
Biosketch |
Selected Publications | Staff |
Enzmann V, Yolcu E, Kaplan HJ, Ildstad ST.
Stem cells as tools in regenerative therapy for retinal degeneration.
Arch Ophthalmol. 2009 Apr;127(4):563-71.
http://www.ncbi.nlm.nih.gov/pubmed/19365041
Yolcu ES, Ash S, Kaminitz A, Sagiv Y, Askenasy N, Yarkoni S.
Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression.
Immunol Cell Biol. 2008 Nov-Dec;86(8):650-8.
http://www.ncbi.nlm.nih.gov/pubmed/18794907
Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H.
Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous Fas ligand protein.
J Immunol. 2008 Jul 15;181(2):931-9.
http://www.ncbi.nlm.nih.gov/pubmed/18606644
Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H.
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8.
http://www.ncbi.nlm.nih.gov/sites/entrez/18058571
Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
J Immunol. 2007 Dec 1;179(11):7295-304.
http://www.ncbi.nlm.nih.gov/sites/entrez/18025172
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N.
Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
Exp Hematol. 2007 Oct;35(10):1601-12.
http://www.ncbi.nlm.nih.gov/sites/entrez/17889725
Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N.
Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors.
Stem Cells. 2007 Dec;25(12):3194-203. Epub 2007 Sep 13.
http://www.ncbi.nlm.nih.gov/sites/entrez/17872500
Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H.
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
J Immunol. 2007 Jun 1;178(11):6840-8.
http://www.ncbi.nlm.nih.gov/sites/entrez/17513732
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N.
Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
Stem Cells. 2007 Jun;25(6):1448-55. Epub 2007 Mar 15.
http://www.ncbi.nlm.nih.gov/sites/entrez/17363551
Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, Askenasy N.
Pancreatic islets under attack: cellular and molecular effectors.
Curr Pharm Des. 2007;13(7):749-60. Review.
http://www.ncbi.nlm.nih.gov/sites/entrez/17346189
Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H.
A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model.
Mol Immunol. 2007 Apr;44(11):2884-92. Epub 2007 Feb 26.
http://www.ncbi.nlm.nih.gov/sites/entrez/17324464
Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.
Hum Gene Ther. 2006 Mar;17(3):334-46.
http://www.ncbi.nlm.nih.gov/sites/entrez/16544982
Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H.
Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.
Exp Mol Pathol. 2006 Jun;80(3):252-61. Epub 2006 Feb 17.
http://www.ncbi.nlm.nih.gov/sites/entrez/16487512
Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N.
The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation.
Bioessays. 2006 Feb;28(2):211-22.
http://www.ncbi.nlm.nih.gov/sites/entrez/16435302
Singh NP, Yolcu ES, Askenasy N, Shirwan H.
ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.
Ann N Y Acad Sci. 2005 Nov;1056:344-58.
http://www.ncbi.nlm.nih.gov/sites/entrez/16387700
Köksoy S, Elpek KG, Yolcu ES, Shirwan H.
Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells.
Transplantation. 2005 Jun 15;79(11):1492-7.
http://www.ncbi.nlm.nih.gov/sites/entrez/15940037
Askenasy N, Yolcu ES, Yaniv I, Shirwan H.
Induction of tolerance using Fas ligand: a double-edged immunomodulator.
Blood. 2005 Feb 15;105(4):1396-404. Epub 2004 Oct 14. Review.
http://www.ncbi.nlm.nih.gov/sites/entrez/15486063
Askenasy N, Yolcu ES, Shirwan H, Stein J, Yaniv I, Farkas DL.
Characterization of adhesion and viability of early seeding hematopoietic cells in the host bone marrow in vivo and in situ.
Exp Hematol. 2003 Dec;31(12):1292-300.
http://www.ncbi.nlm.nih.gov/sites/entrez/14662337
Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H.
A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.
Cancer Res. 2003 Jul 15;63(14):4067-73.
http://www.ncbi.nlm.nih.gov/sites/entrez/12874008
Shirwan H, Mhoyan A, Yolcu ES, Que X, Ibrahim S.
Chronic cardiac allograft rejection in a rat model disparate for one single class I MHC molecule is associated with indirect recognition by CD4(+) T cells.
Transpl Immunol. 2003 Apr-Jun;11(2):179-85.
http://www.ncbi.nlm.nih.gov/sites/entrez/12799202
Shirwan H, Mhoyan A, Kakoulidis TP, Yolcu ES, Ibrahim S.
Prevention of chronic rejection with immunoregulatory cells induced by intrathymic immune modulation with class I allopeptides.
Am J Transplant. 2003 May;3(5):581-9.
http://www.ncbi.nlm.nih.gov/sites/entrez/12752314
Mhoyan A, Wu GD, Kakoulidis TP, Que X, Yolcu ES, Cramer DV, Shirwan H.
Predominant expression of the Th2 response in chronic cardiac allograft rejection.
Transpl Int. 2003 Aug;16(8):464-73. Epub 2003 Apr 24.
http://www.ncbi.nlm.nih.gov/sites/entrez/12712237
Askenasy N, Yolcu ES, Wang Z, Shirwan H.
Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.
Circulation. 2003 Mar 25;107(11):1525-31.
http://www.ncbi.nlm.nih.gov/sites/entrez/12654611
Askenasy N, Yolcu ES, Shirwan H, Wang Z, Farkas DL.
Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients.
Stem Cells. 2003;21(2):200-7.
http://www.ncbi.nlm.nih.gov/sites/entrez/12634416
Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H.
Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection.
Immunity. 2002 Dec;17(6):795-808.
http://www.ncbi.nlm.nih.gov/sites/entrez/12479825